Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract (JANORL2)
Randomized Phase 2 Trial Evaluating the Acute Toxicity of Two Protocols of Reirradiation After Surgery in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract - Single-fraction Radiotherapy With Concomitant 5FU and Hydrea Administered Every Other Week - Continuous Hyperfractionated Radiotherapy With Concomitant Cetuximab
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Villejuif, France, 94800
- Institut Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Recurrent or second upper aerodigestive tract carcinoma in an area previously irradiated at a dose of >= 50 Gy
- Squamous cell carcinoma
- No grade III or IV sequels linked to the first radiation therapy (excepted radiation sequels of salivary glands)
- Relapse or second carcinoma (clinically invasive and/or lymph node recurrence >= 3 cm and/or the association of a local and lymph node recurrence
- Oral cavity, pharynx, larynx (if rT4), cervical region (if >3cm)
- No distant metastases confirmed by chest CT scan, abdominal ultrasound (or CT scan) in case of abnormal liver function, and bone scintigraphy in case of local symptoms
- Surgery in the previously irradiated region allowing a macroscopically adequate resection
- Surgery and vascular protection with a myocutaneous or free flap
- Interval > = 6 months between the end of the first radiation treatment and surgery in the previously irradiated area
- Wound healing allowing reirradiation within an interval of 8 weeks after surgery in the previouly irradiated area.
- No participation in a clinical trial during the 30 days preceding inclusion
- Age between 18 et 70 years.
- Performance Status 0 or 1 according to WHO criteria.
- Hematological function : neutrophils * 2 x 106/l, platelets : * 100 x 106/l, hemoglobin : * 10 g/dl (or 6.2 mmol/l)
- Liver function : total bilirubin (normal) ; ASAT (SGOT) and ALAT (SGPT) * 2.5 * upper limit of normal (ULN) in each centre ; alkaline phosphatases * 5 * ULN. Patients whose ASAT or ALAT levels > 1.5 * ULN associated with alkaline phosphatases * 2.5 * ULN are not eligible for the trial
- Renal function : serum creatinine * 120 *mol/l (1.4 mg/dl) ; if creatinine level is > 120 *mol/l, creatinine clearance should be * 60 ml/min.
- Written consent of participants
Exclusion Criteria:
- Superficial recurrence not associated with a lymph node relapse, isolated lymph node recurrence measuring less than 3 cm
- Distant metastases
- Grade 3 or 4 sequels of first radiation therapy (excepted salivary gland sequels)
- Macroscopically inadequate surgery
- Delay in wound healing obliging reirradiation to be postponed beyond 8 weeks.
- > Grade 3 Toxicity induced by chemotherapy administered during a previous treatment
- Hypersensitivity to Erbitux
- Concomitant severe comorbidities (non exhaustive list)
- Unstable cardiac comorbidity in spite of treatment.
- Neurological or psychiatric history such as dementia, convulsions.
- Severe uncontrolled infection
- Obstructive bronchopneumopathy which required hospitalisation during the year preceding inclusion.
- Factors (psychological, familial, social or geographic) likely to hinder patient compliance with the study protocol and follow-up are considered exclusion criteria. These factors should be discussed with the patient before enrollment in the trial
- Women who are pregnant, breast-feeding or of birthgiving age without effective contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: single-fraction radiotherapy with concomitant 5FU and Hydrea
six 5-day cycles with a 9-day rest period between each cycle (split course).
Each cycle includes : a single-fraction at a dose of 2 Gy per session for 5 sessions, combined with 5FU (800 mg/m2/day) and Hydrea (500 mg x 3/day) over the 5 days of the cycle.
The total dose of radiotherapy is therefore 60 Gy delivered over 11 weeks.
|
single-fraction radiotherapy with concomitant 5FU and Hydrea
|
|
Experimental: hyperfractionated radiotherapy with concomitant Cetuximab
Bifractionated radiotherapy at a dose of 1.2 Gy per session at a rate of 2 sessions per day, at least 6h apart, 5 days per week over 5 weeks, without a split course, combined with Cetuximab.
The total dose of radiotherapy is 60 Gy delivered over 5 weeks.
Cetuximab (ErbituxÒ) is to be administered in a 2-hour IV infusion at a dose of 400 mg/m2, 8 days before the start of radiotherapy, then in a 1-hour infusion at a dose of 250 mg/m2 on days 1, 8, 15, 22 and 29 of radiotherapy.
|
hyperfractionated radiotherapy with concomitant Cetuximab
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Acute toxicity requiring an interruption of radiotherapy for more than 2 weeks
Time Frame: 6 months
|
6 months
|
|
Overall survival at 3 years and loco-regional control at 3 years
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CSET 1542-JANORL2
- 2009-017047-34 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.